LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial
| Autor: | Nathan, P., Dummer, R., Long, G.V., Ascierto, P.A., Tawbi, H.A., Robert, C., Rutkowski, P., Leonov, O., Dutriaux, C., Mandala', M., Lorigan, P., Ferrucci, P.F., Flaherty, K.T., Brase, J.C., Green, S., Haas, T., Masood, A., Gasal, E., Ribas, A., Schadendorf, D. |
|---|---|
| Zdroj: | In Annals of Oncology September 2020 31 Supplement 4:S1172-S1172 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|